about
Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunitiesBiochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decadeVEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissueGelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain.Zymography methods for visualizing hydrolytic enzymes.Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1.Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative studySynthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.Functional links between gelatinase B/matrix metalloproteinase-9 and prominin-1/CD133 in diabetic retinal vasculopathy and neuropathy.On the structure and functions of gelatinase B/matrix metalloproteinase-9 in neuroinflammation.Proteases in cancer drug delivery.Systemic Ablation of MMP-9 Triggers Invasive Growth and Metastasis of Pancreatic Cancer via Deregulation of IL6 Expression in the Bone Marrow.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.Physico-chemical and toxicological characterization of iron-containing albumin nanoparticles as platforms for medical imaging.Intradermal air pouch leukocytosis as an in vivo test for nanoparticles.Differential Diagnosis of Autoimmune Pancreatitis From Pancreatic Cancer by Analysis of Serum Gelatinase Levels.Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis.Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1.Inhibition of MMP-9-dependent Degradation of Gelatin, but Not Other MMP-9 Substrates, by the MMP-9 Hemopexin Domain Blades 1 and 4.Suramin increases cartilage proteoglycan accumulation in vitro and protects against joint damage triggered by papain injection in mouse knees in vivo.Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer.Neutrophils and Activated Macrophages Control Mucosal Immunity by Proteolytic Cleavage of Antileukoproteinase.Matrix Metalloproteinase-9-Generated COOH-, but Not NH2-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity.Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitisInfliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel DiseaseEDTA/gelatin zymography method to identify C1s versus activated MMP-9 in plasma and immune complexes of patients with systemic lupus erythematosusAzithromycin decreases MMP-9 expression in the airways of lung transplant recipientsOncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelinationHomotrimeric MMP-9 is an active hitchhiker on alpha-2-macroglobulin partially escaping protease inhibition and internalization through LRP-1Gelatinase B/matrix metalloproteinase-9 and other neutrophil proteases switch off interleukin-2 activityPropeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase BAuthor's reply: To PMID 24379662
P50
Q26745510-D478A7BF-238B-4D6C-B0E3-A2FDD7C270CDQ28288148-A3622371-1A71-4759-ACF3-C382B8E2AA1DQ30528882-44E10983-27C6-4C82-918F-3557DEB0C2C9Q33887938-EF4EC359-9768-4B60-93C2-84FEA4A6EBF0Q34329995-8F12895D-6FE9-4870-8C98-6641CDF0A954Q35447969-163B3AE0-B847-4FC5-ADFD-356D77F641B4Q36331820-666C4876-CA62-418C-868B-81F6183AF231Q37517611-6F5AB5E4-7838-414B-8914-984761C447E3Q37595298-C1BD2655-5B60-449A-8057-23F885DA3ECEQ38235675-CBF3234D-E5BA-437B-A7F2-116E9D8BA647Q38269693-510D778E-5FF5-4410-A74B-D1671E8838D9Q38693325-54CDAEC9-8BE2-4B25-A58C-396E9672D671Q38734052-3304F851-0294-43C1-B48A-CED6A66DEC13Q38881849-55AC174B-EDCC-4944-8407-AAF977E7A565Q38961400-5FA5E2E1-C61C-4936-BE59-54E6A486CF76Q39282155-050A0C43-1CE9-4D74-BB73-FABED9FC0132Q40182997-7CAE7C25-A5A5-4746-80DA-D00AD74C8C64Q40607435-76C0203B-CEC2-421B-9AD7-90712E3BD521Q42368319-2FA19346-96F6-45DC-9649-CC904DB7DABFQ42571243-917FD3D8-EADF-48E9-8A00-D6FEDBB26D49Q47148493-F5D2DB12-0585-4A8E-A23C-C37C69BB2B84Q51559654-6ADB8C4A-FD3D-46F6-AB54-91400B648831Q54974556-53726F45-0B0C-456A-9017-80564E1ECF22Q55404009-137ADDC5-9745-4439-957A-91A6B207D5EFQ57061847-86E5A67E-639A-482E-8956-E89A883775FAQ57265309-15B5E125-7650-466D-9C72-7C2488BD56B1Q57792121-9FC043B4-E309-4959-9476-67896E8A5B2FQ84527354-D169835F-1417-4E34-8CA2-9B87B1468140Q89766748-180F8203-8A12-4637-82D6-D8968BFD1982Q90901680-EE466AB8-A24C-4267-A399-C4162D8EB549Q91525883-07CDBBB4-76A8-4C15-AA82-605A05A10784Q93031526-B4940B24-08F7-457A-976B-0EC7F0913ADEQ95570610-107D629A-3F4B-4E22-940D-672C95B86E09
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jennifer Vandooren
@ast
Jennifer Vandooren
@en
Jennifer Vandooren
@es
Jennifer Vandooren
@nl
type
label
Jennifer Vandooren
@ast
Jennifer Vandooren
@en
Jennifer Vandooren
@es
Jennifer Vandooren
@nl
prefLabel
Jennifer Vandooren
@ast
Jennifer Vandooren
@en
Jennifer Vandooren
@es
Jennifer Vandooren
@nl
P1053
O-6424-2018
P106
P1153
51764469300
P21
P31
P496
0000-0002-7157-3370